Aim: to evaluate long-term outcomes in patients treated with CA for multiple bilobar CRLM Study data: 415 patients; 291 patients treated with HR and 124 treated with HR + CA Conclusions: median OS 32 moths, 5-year survival with HR and HR + CA were 32% and 24%, respectively (); overall, long-term survival results of HR + CA for multiple bilobar CRLM are comparable to that of HR alone in selected patients
Aim: to evaluate the effects of CA with and without other treatments in HCC Study data: 235 patients; 78 patients treated with CA, 58 patients with CA + HALP, 27 patients treated with CA + surgical resection, and 72 patients treated with CA followed by resection of the frozen tumor Conclusions: CA is as effective as other treatments for treating patients with HCC
Aim: to evaluate the efficacy of CA in patients with cirrhosis and unresectable HCC Study data: 12 patients (stage II, 2; stage III, 1; stage IVA, 7; stage IVB, 2) Conclusions: CA is feasible and safe and is primarily palliative; it may provide cure in selected patients with lower-stage disease
Aim: to evaluate effects of CA and surgical resection for advanced hepatic tumors Study data: 31 patients Conclusions: CA complements surgical resection but can cause significant morbidity especially in patients with advanced unresectable hepatobiliary tumors
Aim: to compare morbidity, mortality, recurrence, and survival between CA and liver resection in patients with liver metastases Study data: 223 patients; 168 patients underwent liver resection and 55 patients had CA Conclusions: survival is comparable in selected patients; however, CA is associated with higher rates of hepatic recurrence; CA may not be suitable for patients with resectable disease
Aim: to evaluate the safety and efficacy of CA in patients with hepatic colorectal metastases Study data: 326 patients treated with CA for unresectable metastatic lesions Conclusions: CA is safe and complements surgical resection in unresectable tumors
Aim: to evaluate incidence, morbidity, and mortality during treatment with CA Study data: 134 centers worldwide (44.8% response); 7605 patients; 2173 patients were treated with hepatic CA Conclusions: serious complication like cryoshock develops in 1% of all patients with hepatic CA; cryoshock is responsible for 18.2% of all deaths associated with this treatment
Aim: to evaluate the effects of CA in patients with primary and secondary liver malignancy Study data: 54 lesions; 19 patients; 17 patients with metastasis, 2 with HCC Conclusions: CA results in high rate of complications and poor long-term tumor control
